Ask AI
ProCE Banner Activity

From Current Standards to Emerging Strategies: Rethinking the HNSCC Treatment Continuum

Clinical Thought

In this activity, experts examine the evolving treatment continuum in head and neck squamous cell carcinoma (HNSCC), with a focus on how biologic factors, treatment setting, and therapeutic sequencing influence clinical decision-making. Expert perspectives address the prognostic and therapeutic implications of HPV status and PD-L1 expression; evidence from studies of immune checkpoint inhibition in locally advanced disease, including the differing results of concurrent, sequential, and perioperative strategies; and the role of pembrolizumab-based therapy in recurrent or metastatic HNSCC, where substantial unmet need remains despite improved outcomes. Faculty also review emerging EGFR-directed and bispecific approaches, including amivantamab, ficerafusp alfa, and petosemtamab, and consider how early response and durability data may inform future treatment strategies as these agents advance into later-phase trials. Together, these data highlight the importance of integrating biomarkers, disease setting, treatment sequencing, and emerging efficacy evidence when selecting therapy and planning care for patients with HNSCC.

Released: August 19, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Supported by an educational grant from Johnson & Johnson.

Johnson & Johnson

Target Audience

This activity is intended for medical oncologists and other healthcare professionals who care for patients with HNSCC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess approved therapies for the treatment of HNSCC to inform the selection of suitable patient candidates for therapeutic intervention   

  • Differentiate current unmet needs in the treatment of head and neck cancer and their impact on care delivery and overall patient outcomes

  • Appraise clinical data regarding the safety and efficacy of emerging targeted and immunotherapeutic agents and next generation radiotherapy modalities in the treatment of HNSCC

Financial Disclosures

Primary Author

Aarti Bhatia, MD, MPH: consultant/advisor/speaker: Adcendo, Regeneron.

Deborah J. Wong, MD, PhD: consultant/advisor/speaker: Bicara, Coherus, Merus, Regeneron; researcher: A2 Biotherapeutics, AstraZeneca, Aveo, Bicara, BioNTech, Gilead, GSK, Johnson & Johnson, Lilly, Merck, Pyxis, Sensei, Tempus, TopAlliance; researcher/consultant: Bicara.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.